*1. Which describes you?
*2. When were you diagnosed with inflammatory bowel disease (Crohn’s disease or ulcerative colitis)?
*3. Patient’s age:
*4. Are you currently taking a biologic therapy?
*5. What is most important to you when deciding on a medication?
*6. How comfortable to do you feel talking to your doctor about biosimilars?
*7. Biosimilars are not generic versions of biologic medications.
*8. Biosimilars have the same effectiveness and safety profile as the originator biologic.
*9. The FDA has approved a biosimilar for Crohn’s disease and ulcerative colitis, however it is not yet available in the U.S.
*10. If a new biosimilar therapy demonstrates similar safety and effectiveness to the originator biologic in rheumatoid arthritis, what is your opinion regarding its use in IBD?
*11. What is your opinion regarding patient and doctor knowledge and choice regarding biosimilar therapies in IBD?
*12. Which of the potential issues around biosimilars would be most important to you?
*13. What other information would you most like to learn about biosimilars?
14. Please tell us how we can improve future programs about biosimilars.
15. Other comments or concerns
*Required Fields

 © Copyright 2018. All rights reserved. Developed and managed by RMEI Medical Education, LLC
Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, New Jersey 08043 |
www.RMEI.com | (866) 770-RMEI